ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Provided By PR Newswire
Last update: Aug 12, 2025
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients
Read more at prnewswire.com
